Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID3860]
Proposed [GID-TA10746] Expected publication date: TBC
Search results
146 results
-
-
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over [ID2704]
Proposed [GID-TA10655] Expected publication date: TBC
-
Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]
Proposed [GID-TA10811] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-negative metastatic or unresectable breast cancer after chemotherapy [ID3935]
Proposed [GID-TA10813] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies [ID3934]
Proposed [GID-TA10814] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3933]
Proposed [GID-TA10815] Expected publication date: TBC
-
Mosunetuzumab for treating relapsed or refractory B-cell non-Hodgkin lymphoma [ID3931]
Proposed [GID-TA10816] Expected publication date: TBC
-
Belzutifan for treating clear-cell renal carcinoma caused by von Hippel-Lindau disease [ID3932]
Proposed [GID-TA10817] Expected publication date: TBC
-
Tofacitinib for treating active ankylosing spondylitis [ID3865]
Proposed [GID-TA10771] Expected publication date: TBC
-
Voxelotor for treating sickle cell disease [ID1403]
Proposed [GID-TA10505] Expected publication date: 10 August 2022
-
Upadacitinib for treating active ankylosing spondylitis [ID3848]
Proposed [GID-TA10735] Expected publication date: TBC
-
Oleogel-S10 for treating skin wounds associated with epidermolysis bullosa [ID1505]
Proposed [GID-TA10654] Expected publication date: TBC
-
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]
Proposed [GID-TA10727] Expected publication date: TBC
-
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]
Proposed [GID-TA10728] Expected publication date: TBC
-
177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]
Proposed [GID-TA10730] Expected publication date: TBC
-
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]
Proposed [GID-TA10763] Expected publication date: TBC
-
Lumasiran for treating primary hyperoxaluria type 1 [ID3765]
Proposed [GID-TA10660] Expected publication date: TBC
-
Ozanimod for treating moderately to severely active ulcerative colitis [ID3841]
Proposed [GID-TA10732] Expected publication date: TBC
-
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer [ID3896]
Proposed [GID-TA10812] Expected publication date: TBC
-
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus [ID3804]
Proposed [GID-TA10676] Expected publication date: 27 April 2022
-
Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis [ID3787]
Proposed [GID-TA10753] Expected publication date: TBC
-
Benralizumab for previously treated severe nasal polyps [ID1659]
Proposed [GID-TA10818] Expected publication date: TBC
-
Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]
Proposed [GID-TA10749] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]
Proposed [GID-TA10826] Expected publication date: TBC
-
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Proposed [GID-TA10764] Expected publication date: 26 January 2022
-
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]
Proposed [GID-TA10657] Expected publication date: TBC
-
Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]
Proposed [GID-TA10535] Expected publication date: TBC
-
Romosozumab for treating severe osteoporosis [ID3936]
Proposed [GID-TA10828] Expected publication date: TBC
-
Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 20 April 2021.
-
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 20 April 2021.
-
Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]
Proposed [GID-TA10777] Expected publication date: TBC
-
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1499]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 28 April 2021.
-
Tirzepatide for treating type 2 diabetes ID3938
Proposed [GID-TA10835] Expected publication date: TBC
-
Sacituzumab govitecan for treating metastatic or unresectable triple-negative breast cancer after 2 or more therapies ID3942
Proposed [GID-TA10829] Expected publication date: TBC
-
Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma ID3940
Proposed [GID-TA10830] Expected publication date: TBC
-
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies ID3943
Proposed [GID-TA10831] Expected publication date: TBC
-
Maralixibat for treating cholestatic disease in Alagille Syndrome ID3941
Proposed [GID-TA10832] Expected publication date: TBC
-
Mavorixafor for treating WHIM syndrome ID3946
Proposed [GID-TA10833] Expected publication date: TBC
-
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome or Alström syndrome ID3947
Proposed [GID-TA10834] Expected publication date: TBC
-
Gefapixant for treating refractory or unexplained chronic cough [ID3789]
Proposed [GID-TA10678] Expected publication date: TBC
-
Foslevodopa-foscarbidopa for treating Parkinson's disease with motor fluctuations [ID3876]
Proposed [GID-TA10772] Expected publication date: TBC
-
Risankizumab for previously treated active psoriatic arthritis [ID1399]
Proposed [GID-TA10819] Expected publication date: TBC
-
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs have failed (partial review of TA375) [ID2710]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 28 April 2021.
-
Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]
Proposed [GID-TA10820] Expected publication date: TBC
-
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]
Proposed [GID-TA10752] Expected publication date: TBC
-
Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 26 April 2021.